Clinical trials: Peyronie Disease
Peyronie's Disease
The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease
This study evaluated the safety and effectiveness of AA4500 in improving the impact of Peyronie's disease on quality of life and improving penile curvature in men with Peyronie's disease
- Trial name
- NCT00755222
- Testing
- AA4500
- Where
- 12 sites in United States
- Volunteers
- 147 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Peyronie's Disease
Study of AA4500 in the Treatment of Peyronie's Disease
This study is a Phase 3, double-blind, randomized, placebo-controlled study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Approximately 400 (267 AA4500 and 133 placebo) men will be randomized.
- Trial name
- NCT01221597
- Testing
- AA4500
- Where
- 34 sites in United States, Australia
- Volunteers
- 418 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Peyronie's Disease
H-22411: BOTOX® for Peyronie's Disease
Peyronie's disease is a condition in which a plaque, or hard lump, forms on the penis. It causes hardened tissue, pain, and an abnormal bending in the penis. These symptoms are more severe during an erection.
- Trial name
- NCT00812838
- Testing
- 100 units of Botulinum Toxin Type A, Preservative free normal saline, 100 units Botulinum Toxin A
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mohit Khera
Peyronie's Disease
A Study of AA4500 in Men With Peyronie's Disease
This study is a Phase 3, open-label study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug…
- Trial name
- NCT01243411
- Testing
- AA4500
- Where
- 39 sites in United States, Denmark and 7 more
- Volunteers
- 348 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Peyronie's Disease
Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease
This study is a Phase 2, open-label study to assess the pharmacokinetics (PK) and safety of AA4500 0.58 mg in men with Peyronie's disease.
- Trial name
- NCT01430169
- Testing
- AA4500
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Peyronie's Disease
A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease
This study is a Phase 3, open-label study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug…
- Trial name
- NCT01685437
- Testing
- AA4500
- Volunteers
- 189 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Peyronie's Disease
Study of AA4500 in the Treatment of Peyronie's Disease
This study is a Phase 3, double-blind, randomized, placebo-controlled study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Approximately 300 (200 AA4500 and 100 placebo) men will be randomized.
- Trial name
- NCT01221623
- Testing
- AA4500
- Where
- 34 sites in United States, Australia
- Volunteers
- 418 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company